Last reviewed · How we verify

Prevymis — Competitive Intelligence Brief

Prevymis (LETERMOVIR) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Cytomegalovirus DNA Terminase Complex Inhibitor [EPC]. Area: Infectious Disease.

marketed Cytomegalovirus DNA Terminase Complex Inhibitor [EPC] Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

Prevymis (LETERMOVIR) — Merck & Co.. Prevymis works by inhibiting the DNA terminase complex of the cytomegalovirus, preventing the virus from replicating.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Prevymis TARGET LETERMOVIR Merck & Co. marketed Cytomegalovirus DNA Terminase Complex Inhibitor [EPC] 2017-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Cytomegalovirus DNA Terminase Complex Inhibitor [EPC] class)

  1. Merck & Co. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Prevymis — Competitive Intelligence Brief. https://druglandscape.com/ci/letermovir. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: